| Title: |
Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. |
| Authors: |
Mittra, Arjun1,2 (AUTHOR), Coyne, Geraldine H. O' Sullivan1 (AUTHOR), Zlott, Jennifer1 (AUTHOR), Kummar, Shivaani1,3 (AUTHOR), Meehan, Robert1 (AUTHOR), Rubinstein, Lawrence4 (AUTHOR), Juwara, Lamin5 (AUTHOR), Wilsker, Deborah6 (AUTHOR), Ji, Jiuping6 (AUTHOR), Miller, Brandon6 (AUTHOR), Navas, Tony6,7 (AUTHOR), Ferry-Galow, Katherine V.6 (AUTHOR), Voth, Andrea Regier8 (AUTHOR), Chang, Ting-Chia9 (AUTHOR), Jiwani, Shahanawaz9 (AUTHOR), Parchment, Ralph E.6 (AUTHOR), Doroshow, James H.1,10 (AUTHOR), Chen, Alice P.1 (AUTHOR) chenali@mail.nih.gov |
| Source: |
Cancer Chemotherapy & Pharmacology. Mar2024, Vol. 93 Issue 3, p177-189. 13p. |
| Subject Terms: |
*DNA repair, *POLY ADP ribose, *POLY(ADP-ribose) polymerase, *MONONUCLEAR leukocytes, *METASTATIC breast cancer, *HORMONE receptor positive breast cancer |
| Abstract: |
Purpose: Talazoparib is an inhibitor of the poly (ADP-ribose) polymerase (PARP) family of enzymes and is FDA-approved for patients with (suspected) deleterious germline BRCA1/2-mutated, HER2‑negative, locally advanced or metastatic breast cancer. Because knowledge of the pharmacodynamic (PD) effects of talazoparib in patients has been limited to studies of PARP enzymatic activity (PARylation) in peripheral blood mononuclear cells, we developed a study to assess tumoral PD response to talazoparib treatment (NCT01989546). Methods: We administered single-agent talazoparib (1 mg/day) orally in 28-day cycles to adult patients with advanced solid tumors harboring (suspected) deleterious BRCA1 or BRCA2 mutations. The primary objective was to examine the PD effects of talazoparib; the secondary objective was to determine overall response rate (ORR). Tumor biopsies were mandatory at baseline and post-treatment on day 8 (optional at disease progression). Biopsies were analyzed for PARylation, DNA damage response (γH2AX), and epithelial‒mesenchymal transition. Results: Nine patients enrolled in this trial. Four of six patients (67%) evaluable for the primary PD endpoint exhibited a nuclear γH2AX response on day 8 of treatment, and five of six (83%) also exhibited strong suppression of PARylation. A transition towards a more mesenchymal phenotype was seen in 4 of 6 carcinoma patients, but this biological change did not affect γH2AX or PAR responses. The ORR was 55% with the five partial responses lasting a median of six cycles. Conclusion: Intra-tumoral DNA damage response and inhibition of PARP enzymatic activity were confirmed in patients with advanced solid tumors harboring BRCA1/2 mutations after 8 days of talazoparib treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Cancer Chemotherapy & Pharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Academic Search Complete |
